Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics.
Eghtesad
B
B
University of New Mexico Health Sciences Center, Albuquerque 87131-5271, USA.
Malhotra
D
D
Hecker
W P
WP
Haq
M
M
Gibel
L J
LJ
Wheeler
D
D
Smith
A Y
AY
Harford
A M
AM
D000293:Adolescent; D000328:Adult; D000368:Aged; D003920:Diabetes Mellitus / Q000453:epidemiology; D003928:Diabetic Nephropathies / Q000453:epidemiology / Q000601:surgery; D005006:Ethnicity; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006630:Hispanic or Latino; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007198:Indians, North American; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009516:New Mexico; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus